Abstract: Methods for screening compounds to treat an oncological disorder regulated through a tumor-inducing pathway are provided. The compounds are administered to non-human animal subjects having a disease model, so that the subjects display pathology symptoms that correspond to the oncological disorder in humans. The subjects carry a regulatable transgene expression, of which is associated with tumor formation, and further carry regulatable genes for suppression of tumor formation. The disease-pathology symptoms are induced using a site-specific recombination system to induce expression of the transgene associated with tumor formation and negatively regulate or eliminate the genes for suppression of the tumor formation. The methods further involve analyzing tumor formation in subjects administered the compound and comparing appearance and amount of tumors in the subjects administered the compound with control subjects not administered the compound.
Abstract: High resolution time sequences of 3D images that show the dynamics of a time varying changes are provided. The 3D time series of images representing an object that include time varying changes may be produced from lower dimensional image time sequences, such as 2D images. The 2D images may be generated using angiography and may include fluid flow information (e.g., arrival times). The fluid flow information may be provided, for example, by injecting a chemical into the fluid and analyzing its position in the object or body over time. A varying contrast model may be applied to determine the location of the chemical at different points in time which may assist in detecting an ailment.
Type:
Grant
Filed:
November 28, 2007
Date of Patent:
April 2, 2013
Assignees:
The Charles Stark Draper Laboratory, Inc., Tufts Medical Center, Inc.
Inventors:
Rami Mangoubi, Mukund Desai, Adel Malek, Andrew Copeland
Abstract: The invention relates generally to G protein coupled receptors and in particular to agonists and antagonists of G protein receptors and methods of using the same.
Abstract: The present invention features a method for identifying a subject with a bicuspid aortic valve (BAV) by detecting one or more single nucleotide polymorphisms (SNPs) present in one or more BAV-associated chromosomal regions (e.g., chromosomal regions containing the AXIN1-PDIA2, ENG, BAT2/3, or ZNF385D gene(s)).
Type:
Application
Filed:
August 20, 2010
Publication date:
February 14, 2013
Applicant:
Tufts Medical Center ,Inc.
Inventors:
Gordon Huggins, Eric Wooten, Michael Mendelsohn
Abstract: A fiberoptic intubating device is provided which permits visualization of the vocal cords and automatic deployment of an endotracheal tube into the trachea upon visualization. The device includes a housing, a handle extending from the housing, and an extendable and retractable stylet extending from the distal end generally in parallel with the longitudinal axis. The device also includes a support member disposed on the housing that is configured to support the endotracheal tube with respect to the housing and to be selectively movable in the longitudinal direction relative to the housing. The device is configured to automatically move the stylet relative to the housing upon actuation of a trigger. Once the stylet is positioned relative to the vocal cords, the device is configured to deploy the endotracheal tube into the trachea upon further actuation of the trigger.
Abstract: The present invention provides for certain polynucleotide sequences that have been correlated to AMD. These polynucleotides are useful as diagnostics, and are preferably used to fabricate an array, useful for screening patient samples. The array is used as part of a laboratory information management system, to store and process additional patient information in addition to the patient's genomic profile. As described herein, the system provides an assessment of the patient's risk for developing AMD, risk for disease progression, and the likelihood of disease prevention based on patient controllable factors.
Type:
Application
Filed:
August 24, 2012
Publication date:
January 24, 2013
Applicants:
THE GENERAL HOSPITAL CORPORATION, TUFTS MEDICAL CENTER, INC.
Abstract: The invention relates generally to G protein coupled receptors and in particular to agonists and antagonists of G protein receptors and methods of using the same.
Abstract: A catheter device for facilitating release of a structure lodged within a body cavity includes a flexible catheter and carrier configured to mount the catheter to a finger. The catheter includes a leading end having an opening configured to permit fluids within the catheter to exit the catheter, and a proximal end configured to connect to a fluid source. A method using the catheter device to release a fetal head from a maternal pelvis during cesarean delivery of the fetus is provided.
Type:
Application
Filed:
May 30, 2012
Publication date:
December 6, 2012
Applicant:
Tufts Medical Center, Inc.
Inventors:
Brigid Kathleen McCue, Matthew McCue Nonnamaker
Abstract: The invention relates generally to G protein coupled receptors and in particular to agonists and antagonists of G protein receptors and methods of using the same.
Abstract: An implantable shunt device for draining cerebrospinal fluid from a patient's subarachnoid space. The device includes a shunt having opposed first and second ends. A one-way valve is located at the first end of the shunt. A helical tip is disposed at the second end. The helical tip is constructed to penetrate a sinus wall of the patient. Upon implantation, a hollow passageway extends between the helical tip and one-way valve such that fluid can be drained through the helical tip and out through the valve. The endovascular cerebrospinal fluid shunt of the present invention can be placed into a patient percutaneously via a catheter inserted into the venous system of the body through a needle hole, without the need for open surgery and the skin incisions required with current shunt devices. The device also allows for more physiologic drainage of cerebrospinal fluid since the device is shunting cerebrospinal fluid into the same cerebral venous system that occurs naturally in normal people.
Abstract: A device for monitoring a heart includes a lead wire having a first end and a second end, the second end in contact with tissue of the heart; a first sensor disposed along the length of the lead wire; and a second sensor disposed at the second end of the lead wire. The first sensor is configured to measure an oxygen content of blood in the heart and the second sensor is configured to measure a fluid pressure in the heart. The device further includes a control module connected to the first end of the lead wire and configured to receive signals related to the measured fluid pressure and the measured oxygen content from the first and second sensors.
Type:
Application
Filed:
October 19, 2010
Publication date:
September 6, 2012
Applicant:
Tufts Medical Center, Inc.
Inventors:
Johanna Paola Contreras, Harry P. Selker
Abstract: The present invention is directed to systems and method for predicting risk of AMD or a susceptibility to AMD in a patient by detecting elevated serum or plasma levels of C3, CFB or CFH and other complement factor polypeptides, wherein devated levels certain complement factors, genetic risk factors, medical risk factors, behavioral and environmental risk factors are associated with are indicative of susceptibility for or an increased risk of developing AMD, or an increased risk of progression of AMD in the patient.
Type:
Application
Filed:
July 30, 2010
Publication date:
July 26, 2012
Applicants:
WASHINGTON UNIVERSITY, TUFTS MEDICAL CENTER, INC.
Inventors:
Johanna M. Seddon, John Patterson Atkinson
Abstract: The present invention discloses the use of bacterial IgA1 proteases to treat IgA1 deposition in tissue and organs. Bacterial IgA1 proteases specifically cleave IgA1 molecules and thus provide a means to specifically cleave and remove IgA1 depositions. Accordingly, therapeutic agents for the treatment of diseases characterized by IgA deposition are provided. In particular, therapeutic agents to treat IgA nephropathy, Dermatitis herpetiformis (DH), and Henoch-Schoenlein purpura (HS) are disclosed.
Abstract: Matrix metalloproteases (MMPs) play many important roles in normal and pathological remodeling processes including atherothrombotic disease, inflammation, angiogenesis and cancer. This invention relates to the activation of protease-activated receptor-1 (PAR-1) by endogenous platelet MMP-1 collagenase on the surface of platelets. Exposure of platelets to fibrillar collagen converts the surface-bound pro-MMP-1 zymogen to active MMP-1, which promotes aggregation through PAR-1, MMP-1 is shown to cleave the PAR-1 extracellular domain at a novel site, which then strongly activates Rho-GTP signaling pathways, cell shape change and motility, and MAPK signaling. Blockade of MMP-PAR 1 suppresses thrombogenesis under arterial flow conditions and inhibited thrombosis in animals. These studies provide a link between matrix-dependent activation of metalloproteases and platelet-G protein signaling and identify MMP-1/PAR-1 as a new target for the treatment and prevention of arterial thrombosis and other thrombotic diseases.
Abstract: Polypeptide agents useful in the treatment of IgA1 deposition diseases and methods of using such polypeptide agents. Methods of screening for inhibitors of IgA1 proteases and agents that inhibit IgA1 proteases are also disclosed.
Type:
Application
Filed:
April 20, 2010
Publication date:
May 10, 2012
Applicant:
TUFTS MEDICAL CENTER, INC.
Inventors:
Todd Holyoak, Jiazhou Qiu, Andrew G. Plaut
Abstract: The present invention features a method of diagnosing elevated left or right ventricular filling pressure and cardiovascular dysfunction in a subject by detecting increased levels of sEng in a biological sample from the subject.
Abstract: A method for fetal monitoring includes acquiring electrical signals from a set of electrodes, for example, a set of surface electrodes applied to a maternal abdominal region. The electrical signals are analyzed, including by performing a morphological analysis of fetal electrocardiogram signals. A clinical indicator is then determined from a result of performing the morphological analysis.
Type:
Application
Filed:
September 30, 2011
Publication date:
April 5, 2012
Applicants:
Tufts Medical Center, Inc., E-Trolz, Inc., Massachusetts Institute of Technology
Inventors:
Adam J. Wolfberg, Gari D. Clifford, Jay Ward
Abstract: Described herein are compositions, kits and methods for diagnosing and tracking the progression of AMD in a subject by detecting the presence or absence of particular lipid metabolism markers associated with AMD. Predictive computer models of disease risk are also disclosed.
Type:
Application
Filed:
March 26, 2010
Publication date:
February 23, 2012
Applicants:
THE GENERAL HOSPITAL CORPORATION, TUFTS MEDICAL CENTER, INC.
Abstract: MicroRNA (miRNA) profiling of cells showed unique miRNA signatures for each of three Akt isoforms. Among differentially regulated miRNA species, the miR-200 family was downregulated in Akt2-expressing cells. Akt1 knockdown inhibited expression of miR-200 and promoted TGF?-induced epithelial-mesenchymal-transition (EMT) and a stem cell like phenotype. Carcinomas developing in MMTV-cErb2/Akt1?/? mice exhibited increased invasiveness because of EMT induced by miR-200 downregulation. EMT was found to be controlled by miRNA species that are regulated by the balance between Akt1 and Akt2, rather than overall Akt levels.
Type:
Application
Filed:
September 30, 2011
Publication date:
January 26, 2012
Applicants:
PRESIDENT AND FELLOWS OF HARVARD COLLEGE, TUFTS MEDICAL CENTER, INC.
Inventors:
Philip N. Tsichlis, Christos Polytarchou, Dimitrios Iliopoulos
Abstract: A method for fetal monitoring includes acquiring electrical signals from a set of electrodes, for example, a set of surface electrodes applied to a maternal abdominal region. The electrical signals are analyzed, including by performing a morphological analysis of fetal electrocardiogram signals. A clinical indicator is then determined from a result of performing the morphological analysis.
Type:
Application
Filed:
May 23, 2011
Publication date:
January 19, 2012
Applicants:
Tufts Medical Center, Inc., E-Trolz, Inc., Massachusetts Institute of Technology
Inventors:
Adam J. Wolfberg, Gari D. Clifford, Jay Ward